Summary
All extracted claims are about pricing, insurance coverage dynamics, and patient comparison behaviors. None of these topics are supported by the provided FDA label sections, so labeling alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Wegovy (semaglutide) is typically priced as a branded, high-cost weight-loss drug.
No pricing/branded/high-cost characterization is present in the provided label sections.
Exact prices for Wegovy vary depending on pharmacy, insurance coverage, and dosage.
The provided label sections contain no pricing information or factors such as pharmacy, insurance, or dosage affecting price.
Drug pricing changes frequently.
The provided label sections do not address pricing-change frequency.
The cost of comparing Wegovy versus other medications depends on the inclusion of lower-cost generics, older weight-loss prescriptions, or off-label GLP-1 options.
The provided label sections do not discuss cost comparisons, generics, older prescriptions, or off-label GLP-1 options.
People usually compare Wegovy against other branded GLP-1/weight-loss drugs.
The provided label sections do not discuss patient/consumer comparison behaviors.
People usually compare Wegovy against other prescription weight-loss medications.
The provided label sections do not discuss patient/consumer comparison behaviors.
People usually compare Wegovy against off-label semaglutide or different formulations.
The provided label sections do not discuss patient/consumer comparison behaviors or off-label formulation comparisons.
Older prescription weight-loss options are often priced lower than Wegovy as brands.
The provided label sections do not contain pricing comparisons with other weight-loss drugs.
Older prescription weight-loss options may have different effectiveness compared with Wegovy.
The provided label sections do not provide comparative effectiveness statements versus other older weight-loss drugs.
Older prescription weight-loss options may have different side-effect profiles compared with Wegovy.
The provided label sections do not provide comparative side-effect profile statements versus other weight-loss drugs.
Older prescription weight-loss options may have different eligibility rules compared with Wegovy.
The provided label sections do not discuss eligibility rules for other weight-loss drugs or comparisons of eligibility frameworks.
Off-label semaglutide or different formulations may sometimes have a lower cash price than Wegovy.
The provided label sections contain no cash-price information and do not discuss off-label formulations pricing.
Off-label semaglutide or different formulations have coverage and dosing regimen differences compared with Wegovy.
The provided label sections do not discuss insurance coverage policies for off-label formulations or dosing regimen differences for non-labeled formulations.
Among weight-loss GLP-1 medicines, the biggest cost differences are driven by brand pricing and rebate structures.
No label content addresses cost drivers such as brand pricing or rebates.
Among weight-loss GLP-1 medicines, cost differences depend on whether an insurance plan covers the drug for obesity/weight management.
No label content addresses insurance coverage determining cost differences.
Among weight-loss GLP-1 medicines, cost differences depend on step-therapy requirements such as prior authorization, documented BMI criteria, or trial of other therapies.
No label content addresses step-therapy, prior authorization, BMI criteria, or trial requirements for cost differences.
Two people can pay very different amounts for the same drug depending on insurance rules and pharmacy pricing.
No label content addresses patient payment variability, insurance rules, or pharmacy pricing.
Monthly cost for Wegovy can change with titration and dosage strength.
No label content relates titration/dose strength to monthly cost.
Prices differ by country.
No label content addresses international pricing differences.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern pricing/coverage/comparison behavior rather than medication safety, dosing, contraindications, or administration. While they are not label-supported, the provided label excerpts do not indicate direct clinical harm from these specific statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
All claims are real-world pricing/coverage/comparison assertions that are not supported by the provided FDA label sections.
Suggested Improvement
Remove or rephrase pricing, insurance coverage, rebate/step-therapy/country price, and “people usually compare” statements unless you can cite FDA label language provided in the prompt (or other appropriately substantiated, non-label sources).